Faros MT Limited
UkraineAll drugs from this manufacturer
-
The drug is prescribed for adult men for the treatment of metastatic hormone-sensitive prostate cancer, as well as for the treatment of non-metastatic and metastatic castration-resistant prostate cancer (including cases where the disease progresses during androgen deprivation therapy or after docetaxel chemotherapy).
Dosage form: tablets, film-coated
Active substance Dosage enzalutamide 40 mg ATC: L02BB04
-
The drug is prescribed for adult men for the treatment of metastatic hormone-sensitive prostate cancer, as well as for the treatment of non-metastatic and metastatic castration-resistant prostate cancer (with or without symptoms).
Dosage form: tablets, film-coated
Active substance Dosage enzalutamide 80 mg ATC: L02BB04
-
The drug is prescribed for adult women with HER2-positive breast cancer. It is used as part of combination therapy with capecitabine, trastuzumab, or aromatase inhibitors, depending on the type and stage of the disease.
Dosage form: tablets, film-coated
Active substance Dosage lapatinib 250 mg ATC: L01XE07
-
The drug is used for the treatment of advanced or metastatic renal cell carcinoma, as well as for patients with advanced soft tissue sarcoma who have previously undergone chemotherapy (with the exception of certain tumor types, such as liposarcoma).
Dosage form: tablets, film-coated
Active substance Dosage pazopanib 200 mg ATC: L01EX03
-
The drug is used for the treatment of advanced or metastatic renal cell carcinoma, as well as for patients with advanced soft tissue sarcoma who have previously undergone chemotherapy (with the exception of certain tumor types, such as liposarcoma).
Dosage form: tablets, film-coated
Active substance Dosage pazopanib 400 mg ATC: L01EX03